{"id":"placebo-valacyclovir","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Renal dysfunction"},{"rate":null,"effect":"Thrombotic thrombocytopenic purpura (rare)"}]},"_chembl":{"chemblId":"CHEMBL1349","moleculeType":"Small molecule","molecularWeight":"324.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Valacyclovir is converted to acyclovir in vivo, which selectively inhibits viral DNA polymerase and prevents herpes simplex virus replication. In this phase 3 trial context, the placebo arm serves as a control to evaluate whether the antiviral component provides therapeutic benefit, likely in combination with an immunotherapeutic approach by Candel Therapeutics.","oneSentence":"Valacyclovir is an antiviral prodrug that inhibits herpes simplex virus DNA polymerase, while the placebo control allows assessment of the combination's efficacy in a phase 3 trial.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:51:44.703Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Likely oncolytic virus-based immunotherapy in combination with valacyclovir (specific indication unknown without trial details)"}]},"trialDetails":[{"nctId":"NCT07363031","phase":"PHASE2","title":"Oral Herpesviruses and Oral Mucositis in Patients Receiving Head and Neck Radiotherapy","status":"ENROLLING_BY_INVITATION","sponsor":"Instituto Oncoclinicas","startDate":"2022-09-05","conditions":"Oral Mucositis, Head and Neck Cancer (H&N), Radiotherapy Side Effects","enrollment":84},{"nctId":"NCT04710030","phase":"PHASE2","title":"Valacyclovir for Mild Cognitive Impairment","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2021-02-01","conditions":"Mild Cognitive Impairment, Herpes Simplex 1, Herpes Simplex 2","enrollment":50},{"nctId":"NCT05452928","phase":"PHASE4","title":"Aciclovir Versus Placebo for HSV-2 Meningitis","status":"NOT_YET_RECRUITING","sponsor":"Jacob Bodilsen","startDate":"2026-06-01","conditions":"Herpes Simplex 2, Meningitis, Viral","enrollment":150},{"nctId":"NCT03282916","phase":"PHASE2","title":"Anti-viral Therapy in Alzheimer's Disease","status":"COMPLETED","sponsor":"Columbia University","startDate":"2018-02-12","conditions":"Alzheimer Disease, Herpes Simplex 1, Herpes Simplex 2","enrollment":120},{"nctId":"NCT02768363","phase":"PHASE2","title":"Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Candel Therapeutics, Inc.","startDate":"2016-05","conditions":"Prostate Cancer","enrollment":187},{"nctId":"NCT01436968","phase":"PHASE3","title":"Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Candel Therapeutics, Inc.","startDate":"2011-09","conditions":"Prostate Cancer","enrollment":711},{"nctId":"NCT07014397","phase":"NA","title":"Effect of Valaciclovir on Inter-Appointment Pain in Endodontic Treatment of Necrotic Teeth","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2024-11-01","conditions":"Symptomatic Apical Periodontitis","enrollment":38},{"nctId":"NCT05266040","phase":"PHASE2","title":"Valacyclovir in Pain Management of Acute Apical Abscesses","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-10-25","conditions":"Acute Apical Abscess, Pain, Acute","enrollment":60},{"nctId":"NCT03134196","phase":"PHASE4","title":"Zoster Eye Disease Study","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2017-08-23","conditions":"Herpes Zoster Ophthalmicus","enrollment":527},{"nctId":"NCT06316843","phase":"PHASE2","title":"Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2","status":"COMPLETED","sponsor":"Bateman Horne Center","startDate":"2023-10-15","conditions":"Long COVID, PASC Post Acute Sequelae of COVID 19","enrollment":59},{"nctId":"NCT05446571","phase":"PHASE3","title":"Prenatal Treatment of Congenital Cytomegalovirus Infection with Letermovir Versus Valaciclovir","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-10-20","conditions":"Pregnant Women, CMV Infected Fetuses","enrollment":46},{"nctId":"NCT04640571","phase":"PHASE4","title":"Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2021-04-01","conditions":"Bile Salt Export Pump (BSEP) Transporter, Polysorbate 80","enrollment":18},{"nctId":"NCT05902208","phase":"PHASE3","title":"Contribution of an Antiviral Drug (Valaciclovir) in the Treatment of Generalized Periodontitis (Stage III or IV and Grade A, B or C): Prospective, Randomized and Double Blind Clinical Trial","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2024-02-05","conditions":"Periodontitis Chronic Generalized Severe","enrollment":142},{"nctId":"NCT05712343","phase":"EARLY_PHASE1","title":"The Efficacy of Systemic Valacyclovir (Valtrex) on Periodontitis","status":"UNKNOWN","sponsor":"University of California, San Francisco","startDate":"2023-05-25","conditions":"Severe Periodontitis","enrollment":40},{"nctId":"NCT02738229","phase":"PHASE2","title":"Should We Use Oral Valacyclovir in Acute Herpetic Gingivostomatitis in Children?","status":"COMPLETED","sponsor":"St. Justine's Hospital","startDate":"2016-07","conditions":"Herpetic Gingivostomatitis","enrollment":80},{"nctId":"NCT04165122","phase":"PHASE2","title":"Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection","status":"COMPLETED","sponsor":"Heidelberg ImmunoTherapeutics GmbH","startDate":"2019-11-15","conditions":"Herpes Genitalis","enrollment":122},{"nctId":"NCT00079911","phase":"PHASE4","title":"A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2004-03-12","conditions":"Herpes Genitalis","enrollment":7},{"nctId":"NCT03699904","phase":"PHASE2","title":"Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control Trial","status":"TERMINATED","sponsor":"Belfast Health and Social Care Trust","startDate":"2018-10-11","conditions":"COPD, EBV","enrollment":85},{"nctId":"NCT02351102","phase":"PHASE2, PHASE3","title":"Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy","status":"COMPLETED","sponsor":"Rabin Medical Center","startDate":"2015-11","conditions":"Congenital Cytomegalovirus Infection","enrollment":100},{"nctId":"NCT00158860","phase":"PHASE4","title":"A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-06-21","conditions":"Herpes Genitalis","enrollment":384},{"nctId":"NCT02008773","phase":"PHASE2","title":"A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia","status":"COMPLETED","sponsor":"Indiana University","startDate":"2014-03-26","conditions":"Schizophrenia","enrollment":170},{"nctId":"NCT00530777","phase":"PHASE2","title":"HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding","status":"COMPLETED","sponsor":"University of Washington","startDate":"2008-04","conditions":"HIV Infections, Herpes Simplex","enrollment":148},{"nctId":"NCT00514449","phase":"PHASE2","title":"Systematic Evaluation of Antiviral Medication in Schizophrenia","status":"COMPLETED","sponsor":"Konasale Prasad","startDate":"2007-06","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":31},{"nctId":"NCT00860977","phase":"PHASE3","title":"Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals?","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2010-03","conditions":"HIV Infection, Herpes Simplex Type II, HIV Infections","enrollment":202},{"nctId":"NCT00116844","phase":"PHASE4","title":"VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03-29","conditions":"Infections, Herpesviridae","enrollment":73},{"nctId":"NCT00486200","phase":"PHASE2","title":"A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-06-21","conditions":"Herpes Genitalis","enrollment":695},{"nctId":"NCT00803543","phase":"NA","title":"Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2009-01","conditions":"HIV, HIV Infections","enrollment":103},{"nctId":"NCT00428298","phase":"PHASE2","title":"Research Study of Bipolar Mood Symptoms and Cognitive Problems","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2007-03","conditions":"Bipolar Disorder","enrollment":60},{"nctId":"NCT01364792","phase":"PHASE2","title":"To Rescue Cognition With Valaciclovir","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2011-04","conditions":"Schizophrenia, Psychosis","enrollment":24},{"nctId":"NCT01453075","phase":"PHASE1","title":"Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2011-11","conditions":"Chronic Hepatitis C Infection","enrollment":31},{"nctId":"NCT01794897","phase":"PHASE4","title":"Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2013-02","conditions":"Herpes Simplex, Schizophrenia, Schizoaffective Disorder","enrollment":134},{"nctId":"NCT01580995","phase":"PHASE2","title":"Herpes Simplex Type 1 Suppression in Hepatitis C","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2012-04","conditions":"Chronic Hepatitis C Infection","enrollment":19},{"nctId":"NCT01176409","phase":"PHASE3","title":"Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2010-09","conditions":"Human Immunodeficiency Virus, Herpes Simplex","enrollment":60},{"nctId":"NCT00900783","phase":"PHASE2","title":"A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-05","conditions":"Herpes Zoster, Shingles","enrollment":350},{"nctId":"NCT00465205","phase":"PHASE3","title":"HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1 Co-infected Persons","status":"COMPLETED","sponsor":"University of Washington","startDate":"2005-01","conditions":"HIV Infections, Herpes Simplex, Sexually Transmitted Diseases","enrollment":20},{"nctId":"NCT00378976","phase":"PHASE3","title":"HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men.","status":"COMPLETED","sponsor":"University of Washington","startDate":"2003-08","conditions":"HIV Infection, Herpes Simplex, Sexually Transmitted Diseases","enrollment":20},{"nctId":"NCT00870441","phase":"PHASE1","title":"Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers","status":"TERMINATED","sponsor":"Astellas Pharma Inc","startDate":"2009-03","conditions":"Safety of ASP2151","enrollment":442},{"nctId":"NCT01037712","phase":"PHASE4","title":"In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-09","conditions":"Viral Disease, Cytomegalovirus Infection","enrollment":6},{"nctId":"NCT00031486","phase":"PHASE3","title":"Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-09","conditions":"Encephalitis","enrollment":91},{"nctId":"NCT00946556","phase":"NA","title":"Examining the Ability of Herpes Simplex Virus Type 2 (HSV2) Therapy to Reduce HIV Target Cell Numbers in the Cervix","status":"COMPLETED","sponsor":"University of Toronto","startDate":"2010-04","conditions":"Herpes Simplex Type Two Infection, HIV Infections","enrollment":30},{"nctId":"NCT00682721","phase":"NA","title":"Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women","status":"WITHDRAWN","sponsor":"University of Pittsburgh","startDate":"2009-02","conditions":"Bacterial Vaginosis, Herpes Simplex Virus Type II","enrollment":""},{"nctId":"NCT00306787","phase":"PHASE3","title":"Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-03","conditions":"Genital Herpes","enrollment":1179},{"nctId":"NCT00652184","phase":"PHASE2","title":"Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)","status":"UNKNOWN","sponsor":"aRigen Pharmaceuticals, Inc.","startDate":"2008-03","conditions":"Herpes Zoster, Postherpetic Neuralgia","enrollment":300},{"nctId":"NCT00510263","phase":"PHASE4","title":"Scandinavian Bell's Palsy Study","status":"COMPLETED","sponsor":"Uppsala University Hospital","startDate":"2001-05","conditions":"Bell's Palsy","enrollment":839},{"nctId":"NCT00297011","phase":"PHASE2","title":"Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis","status":"COMPLETED","sponsor":"University of Utah","startDate":"2004-09","conditions":"Herpes Labialis","enrollment":300},{"nctId":"NCT00001649","phase":"PHASE3","title":"Valaciclovir to Prevent Transmission of Herpes Simplex Virus","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1997-08","conditions":"Herpes Simplex","enrollment":180},{"nctId":"NCT00161434","phase":"PHASE4","title":"A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons","status":"COMPLETED","sponsor":"University of Washington","startDate":"2003-03","conditions":"Herpes Simplex, HIV Infections","enrollment":60},{"nctId":"NCT00587496","phase":"PHASE1","title":"30-Day Trial of Oral Valtrex or Valtrex Plus Aspirin on Shedding of HSV DNA in Tears and Saliva of Volunteers","status":"UNKNOWN","sponsor":"National Eye Institute (NEI)","startDate":"2006-04","conditions":"Herpes Simplex","enrollment":60},{"nctId":"NCT00561106","phase":"NA","title":"Prednisone-Placebo vs Prednisone-Valacyclovir in Bell´s Palsy","status":"COMPLETED","sponsor":"Universidad de la Republica","startDate":"2002-12","conditions":"Bell´s Palsy","enrollment":42},{"nctId":"NCT00005663","phase":"PHASE3","title":"A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients","status":"UNKNOWN","sponsor":"Glaxo Wellcome","startDate":"1999-06","conditions":"Herpes Simplex, HIV Infections, Herpes Genitalis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":134,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo + valacyclovir","genericName":"Placebo + valacyclovir","companyName":"Candel Therapeutics, Inc.","companyId":"candel-therapeutics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Valacyclovir is an antiviral prodrug that inhibits herpes simplex virus DNA polymerase, while the placebo control allows assessment of the combination's efficacy in a phase 3 trial. Used for Likely oncolytic virus-based immunotherapy in combination with valacyclovir (specific indication unknown without trial details).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}